Pfizer Inc. (PFE)
Pfizer Inc. (PFE) UBS Global Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) UBS Global Healthcare Conference November 13, 2024 3:30 PM ET Company Participants Aamir Malik - Chief Commercial Officer US Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're at the half hour.
Down -11.04% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
Pfizer (PFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Should Value Investors Buy Pfizer (PFE) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Down -9.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Exclusive: Pfizer explores sale of hospital drugs unit, sources say
Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.
Pfizer: The Tide Finally Turning
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant. With business and stock excess seemingly totally wrung out, and with expectations now about as low as ever, long-term investors holding or buying from this starting point could be positioned well, as Pfizer has recently shown exciting signs of bouncing back into growth. Pfizer has increased its dividend for 14 consecutive years, with a 10-year dividend growth rate of 10.2%.
Opinion: Pfizer (PFE) Stock Will Hit $22 Before It Hits $33 During Trump's Presidency
Donald Trump's electoral victory has shaken the market, mostly in a good way.
Relative Strength Alert For Pfizer
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Pfizer presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
Pfizer: Discounted For A Reason - But Dividend Story Remains Rich
PFE's core portfolio and strategic acquisitions continue to deliver decent results, no matter the lumpy sales contribution from Comirnaty and Paxlovid. The company raised their FY2024 core portfolio sales guidance, with the richer adj EPS numbers signaling the management's promising progress in cost and operational optimization. Even so, PFE continues to face massive patent cliff headwinds through 2030, with $31.58B of its annualized FQ3'24 revenues at stake.
2 Healthcare Dividend Stocks That Are Screaming Buys in November
One stock yields 6% today. Another has grown its dividend by 460% over the past decade.
3 Reasons Pfizer Looks Like a No-Brainer Buy Right Now
Pfizer is trading above its 52-week low but is still a dirt cheap buy.
PFE or NVO: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
